Delving into the Latest Updates on TR Therapeutics, Inc. with Synapse

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial.

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

开始日期2016-11-01

申办/合作机构

SerenaGroup, Inc.

[+1]

NCT00792688 / Completed临床2期

Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 0.1% and 1.0% Topically Applied GLYC-101, Compared to Placebo, in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids.

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

开始日期2008-10-01

申办/合作机构

TR Therapeutics, Inc.

NCT00656474 / Completed临床1/2期

Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.

Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.

开始日期2008-03-01

申办/合作机构

TR Therapeutics, Inc.

100 项与 TR Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 TR Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 TR Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 TR Therapeutics, Inc. 相关的转化医学

登录后查看更多信息